Cell line · CVCL_1662
Papers43
1 to 20 of 43
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1ß positive clear cell carcinoma. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma. | Gynecol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. | Cancer Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study. | Cancer Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. | Gynecol Oncol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. | Cell Rep | 2018 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1662/papers